Aardvark Therapeutics, Inc. AARD

Annual Quarterly

FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 23, 2026

Aardvark Therapeutics, Inc. (AARD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $57.6 million. Free cash flow was -$54.3 million. As of Jun 30, 2026 it held $73.9 million in cash and investments and $677,000 in total debt.

Revenue (TTM)
$0
Net income (TTM)
$-69.89M
Operating cash flow (TTM)
$-69.41M
Free cash flow (TTM)
$-69.41M
EPS (TTM)
$-3.21
Dividend per share
None
Shares outstanding
21.82M
Net cash
$73.19M
as of Jun 30, 2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AARD (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
, Emerging growth company
SEC CIK
1774857

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Revenue
$0
Operating income
-$62.7M
Net income
-$57.6M
Diluted EPS
-$2.93
Operating cash flow
-$54.2M
Free cash flow
-$54.3M
Total assets
$117.2M
Total liabilities
$10.5M
Stockholders' equity
$106.6M
Cash and investments
$110.0M
Total debt
$441,000

Recent SEC filings

Form Description Filed Period
8-K Current report
Other events
 Oct 23, 2026 Oct 23, 2026
8-K Current report
Other events
 Oct 22, 2026 Oct 22, 2026
8-K Current report
Officer or director change, Other events
 Oct 8, 2026 Oct 6, 2026
8-K Current report
Shareholder vote results
 Aug 17, 2026 Aug 14, 2026
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 11, 2026 Aug 11, 2026

All 114 Aardvark Therapeutics, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.